Certara (CERT) Q2 2026 earnings review
A Messy Transition Year Underway
Certara’s Q2 results confirm 2026 is a transitional “show-me” year. Following the divestiture of its Regulatory and Medical Writing business, continuing operations eked out a meager 1% YoY revenue growth. The underlying narrative is severely split: the core Software segment is growing, but Services demand is contracting. The company's bottom line was hit hard by $3.2M in reorganization costs, $0.7M in executive recruiting fees, and contingent consideration adjustments, driving a GAAP net loss of $6.1M. Management is trying to buy patience by aggressively repurchasing shares and executing a 5% workforce reduction, but the promised AI-driven “double-digit growth” remains nowhere in sight.
🐂 Bull Case
Software bookings grew 9% YoY following a strong Q1, indicating that demand for core tools like Phoenix and Simcyp remains resilient despite broader industry caution.
Management executed a 5% global workforce reduction focused on overhead, expected to yield $13 million in run-rate savings and support the 29-31% FY EBITDA margin target.
🐻 Bear Case
Services revenue dropped 3% YoY, and bookings fell 6%. Clients are delaying discretionary spending, threatening the second-half revenue ramp.
Net income fell from $1.5M a year ago to a $6.1M loss, weighed down by heavy restructuring, executive turnover, and acquisition-related costs.
⚖️ Verdict: ⚪
Neutral. The divestiture of the lumpy medical writing business clears the deck, and software metrics look healthier. However, a contracting Services segment, falling Adjusted EBITDA, and flat revenue growth mean investors should wait for clear evidence of execution before buying into the AI turnaround story.
Key Themes
Services Segment Lags the Recovery
While software recovers, the Services division is becoming a major drag. Services bookings declined 6% YoY to $47.6M, decelerating further from the weakness observed in Q1. Because services revenue relies heavily on backlog conversion, these back-to-back quarters of booking declines practically guarantee muted services growth for the rest of the year. This directly contradicts the bullish narrative that biopharma clients are eagerly leaning into outsourced, model-informed drug development (MIDD).
Software Engine Shows Durability
Software remains the bright spot. Bookings accelerated 9% YoY to $50.7M. This proves that despite budget constraints, customers view Certara’s core R&D software as indispensable infrastructure. By stripping away the divested medical writing unit, Certara's financial profile is now increasingly anchored by this higher-margin, stickier software revenue.
Forcing Profitability via Restructuring
Faced with stagnant top-line growth, Certara is pulling the cost lever. A 5% reduction in force (RIF) targeting overhead was executed in Q2, which management claims will generate $13 million in run-rate savings. This is critical to offsetting the stranded costs from the recent divestiture and protecting the company's EBITDA margins as it transitions its go-to-market model.
Margin Compression and One-Off Costs
Adjusted EBITDA dropped 3% YoY to $26.2M. Below the adjusted line, the financials are incredibly noisy: Q2 saw $3.2M in reorganization expenses and $0.7M in executive recruiting fees. The company's adjusted EBITDA margin has been steadily decelerating, dropping to roughly 28% in Q2, forcing reliance on the new cost-cutting initiatives to hit the 30% full-year midpoint guide.
AI Innovation: NVIDIA BioNeMo Integration
Certara is pushing hard to establish itself as the premier AI player in drug development. Management explicitly highlighted their new partnership to integrate NVIDIA's BioNeMo Agent Toolkit. While the timeline for direct monetization remains opaque, this validates Certara's technological foundation and positions the company to capture future R&D spend as pharma increasingly relies on accelerated computing to replace human trials.
Massive Execution Risk at the Top
Certara is currently juggling a CEO who is less than a year into the job, a newly appointed Chief Commercial Officer (Julien Perrier), a new CIO, a corporate split into two new divisions (MID3 and ACE), a divestiture, and a 5% workforce reduction. Simultaneously executing this many structural changes while trying to re-accelerate sales is a massive operational risk that could easily result in further commercial disruption.
Other KPIs
The company completed its previously authorized $100 million repurchase program and the Board immediately authorized a new $50 million tranche. While it demonstrates management's belief that the stock is undervalued, it also highlights a lack of near-term, high-return M&A opportunities in the current macro environment.
Decelerating. Down slightly from $12.7 million in the prior year quarter. Adjusted diluted EPS remained flat YoY at $0.08, artificially supported by a lower share count from the buyback program rather than fundamental earnings growth.
Guidance
Stable. The company reaffirmed its 0% to 4% growth target. With Q2 coming in at 1% growth, this implies management expects a modest acceleration in the back half of the year, heavily dependent on converting the strong recent software bookings into recognized revenue.
Reversing/Decelerating. To hit the midpoint of 30%, margins must expand materially in the second half from Q2's ~28.1%. Management is betting entirely on the $13 million in run-rate savings from the Q2 layoffs to bridge this gap.
Stable. Updated to reflect only continuing operations. At the midpoint ($0.335), it reflects a depressed profitability profile for a software business, held back by higher interest expenses and restructuring drags.
Key Questions
Services Backlog Health
With Services bookings declining 6% this quarter and 14% last quarter, how much visibility do you actually have into H2 services revenue, and is there a risk of outright contraction in that segment?
Disruption from Reorganization
You've executed a 5% RIF, divested a major business unit, and realigned the sales force under a new CCO. What specific metrics are you tracking to ensure this massive internal disruption isn't the root cause of the current sluggish growth?
NVIDIA Partnership Economics
While the NVIDIA BioNeMo integration sounds promising technologically, how exactly does Certara plan to monetize this? Will it drive higher software ASPs, or is it purely a defensive move to protect market share?